HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Matthew Caufield has downgraded Aldeyra Therapeutics (NASDAQ: ALDX) from a Buy rating to Neutral. The price target for the stock has been significantly reduced from $10 to $2.